Immunogenic Hepatitis E Virus Polypeptides for Vaccine and Diagnostics Development
This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.
Potential Commercial Applications: | Competitive Advantages: |
|
|
Development Stage:
In vitro data available
Inventors:
Howard Fields (CDC) ➽ more inventions...
Yury Khudyakov (CDC) ➽ more inventions...
Jihong Meng (CDC) ➽ more inventions...
Intellectual Property:
US Application No. 10/257,044
PCT Application No. PCT/US01/010696
US Application No. 60/195,380
Various international patents issued
Publications:
Meng J, et al. PMID 11601892
Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:
OTT Reference No: E-152-2013-0
Updated: Jan 20, 2014